Merrill Lynch maintains buy on Genentech

Merrill Lynch analyst Eric Ende kept Genentech Inc. at a buy rating. He noted data showing Lucentis' ability to treat age-related blindness using quarterly as opposed to monthly dosing did not appear to be as robust as with monthly dosing. But Merrill Lynch said patients will be treated when physicians deem it necessary based on retinal scans, not based on fixed dosing schedules. Thus, Lucentis will dominate the market due to its strong efficacy. Shares of the San Francisco-based pharmaceutical company were down $0.32, or 0.39%, at $82.29 on volume of 3,013,400 shares versus the three-month running average of 3,555,370 shares. (Nasdaq: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.